Current research has demonstrated the definitive presence of oxidative stress in multiple sclerosis (MS). This finding has led to clinical trial research which has indicated that specific antioxidants have the ability to effectively reduce markers of oxidative stress. However, few interventions testing antioxidant supplements have shown efficacy for reducing the symptom burden in the disorder. This paper quickly reviews what is currently known about oxidative stress and antioxidants in MS, explains which nutrients are critical for the creation and maintenance of the myelin sheath, describes potential negative effectors in the diet which may be contributing to oxidative stress, and how these aspects of diet, combined with current knowledge on antioxidants, may be able to be combined into a whole food dietary intervention which can be tested for efficacy in MS.
DoshiAChatawayJ.Multiple sclerosis, a treatable disease. Clin Med (Lond)2016; 16: s53–s59.
2.
Gilgun-SherkiYMelamedEOffenD.The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy. J Neurol2004; 251(3): 261–268.
3.
SanoobarMEghtesadiSAzimiA, et al. Coenzyme Q10 supplementation reduces oxidative stress and increases antioxidant enzyme activity in patients with relapsing–remitting multiple sclerosis. Int J Neurosci2013; 123: 776–782.
4.
SanoobarMEghtesadiSAzimiA, et al. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: A double blind, placebo, controlled randomized clinical trial. Nutr Neurosci2015; 18: 169–176.
5.
SanoobarMDehghanPKhaliliM, et al. Coenzyme Q10 as a treatment for fatigue and depression in multiple sclerosis patients: A double blind randomized clin ical trial. Nutr Neurosci2016; 19: 138–143.
6.
LoveraJRamosADevierD, et al. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies. J Neurol Sci2015; 358: 46–52.
7.
Ramirez-RamirezVMacias-IslasMAOrtizGG, et al. Efficacy of fish oil on serum of TNFα, IL-1β, and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b. Oxid Med Cell Longev2013; 2013: 709493.
8.
Sorto-GomezTEOrtizGGPacheco-MoisesFP, et al. Effect of fish oil on glutathione redox system in multiple sclerosis. Am J Neurodegener Dis2016; 5(2): 145–151.
9.
Zandi-EsfahanSFazeliMShaygannejadV, et al. Evaluating the effect of adding Fish oil to Fingolimod on TNF-α, IL1β, IL6, and IFN-γ in patients with relapsing-remitting multiple sclerosis: A double-blind randomized placebo-controlled trial. Clin Neurol Neurosurg2017; 163: 173–178.
10.
JohnsonSKDiamondBJRauschS, et al. The effect of Ginkgo biloba on functional measures in multiple sclerosis: A pilot randomized controlled trial. Explore (NY)2006; 2(1): 19–24.
11.
LoveraJBagertBSmootK, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: A randomized, placebo-controlled trial. Mult Scler2007; 13(3): 376–385.
12.
LoveraJFKimEHerizaE, et al. Ginkgo biloba does not improve cognitive function in MS: A randomized placebo-controlled trial. Neurology2012; 79: 1278–1284.
13.
KhaliliMEghtesadiSMirshafieyA, et al. Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial. Nutr Neurosci2014; 17(1): 16–20.
14.
KhaliliMAzimiAIzadiV, et al. Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: A double-blind, placebo-controlled, randomized clinical trial. Neuroimmunomodulation2014; 21(6): 291–296.
15.
KhaliliMSoltaniMMoghadamSA, et al. Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial. Electron Physician2017; 9(7): 4899–4905.
16.
MillerEWalczakAMajsterekI, et al. Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course. J Neuroimmunol2013; 257(1–2): 97–101.
17.
Adamczyk-SowaMPierzchalaKSowaP, et al. Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients. J Physiol Pharmacol2014; 65(4): 543–550.
18.
Adamczyk-SowaMPierzchalaKSowaP, et al. Melatonin acts as antioxidant and improves sleep in MS patients. Neurochem Res2014; 39(8): 1585–1593.
19.
RoostaeiTSahraianMAHajeaghaeeS, et al. Impact of melatonin on motor, cognitive and neuroimaging indices in patients with multiple sclerosis. Iran J Allergy Asthma Immunol2015; 14(6): 589–595.
20.
Adamczyk-SowaMSowaPAdamczykJ, et al. Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone. J Physiol Pharmacol2016; 67(2): 235–242.
21.
JafariradSSiassiFHarirchianMH, et al. The effect of vitamin a supplementation on biochemical parameters in multiple sclerosis patients. Iran Red Crescent Med J2013; 15(3): 194–198.
22.
MunzelTDaiberA.Environmental stressors and their impact on health and disease with focus on oxidative stress. Antioxid Redox Signal2018; 28(9): 735–740.
23.
LeeSQTanTSKawamukaiM, et al. Cellular factories for coenzyme Q10 production. Microb Cell Fact2017; 16(1): 39.
24.
AndersonEJThayneKAHarrisM, et al. Do fish oil omega-3 fatty acids enhance antioxidant capacity and mitochondrial fatty acid oxidation in human atrial myocardium via PPARgamma activation. Antioxid Redox Signal2014; 21(8): 1156–1163.
25.
Droy-LefaixMT.Effect of the antioxidant action of Ginkgo biloba extract (EGb 761) on aging and oxidative stress. Age (Omaha)1997; 20(3): 141–149.
26.
BiewengaGPHaenenGRBastA.The pharmacology of the antioxidant lipoic acid. Gen Pharmacol1997; 29(3): 315–331.
27.
ReiterRJMayoJCTanDX, et al. Melatonin as an antioxidant: Under promises but over delivers. J Pineal Res2016; 61(3): 253–278.
28.
MacrezRStysPKVivienD, et al. Mechanisms of glutamate toxicity in multiple sclerosis: Biomarker and therapeutic opportunities. Lancet Neurol2016; 15(10): 1089–1102.
29.
HuskissonEMagginiSRufM.The role of vitamins and minerals in energy metabolism and well-being. J Int Med Res2007; 35(3): 277–289.
30.
AmaralAITavaresJMSonnewaldU, et al. Oligodendrocytes: Development, physiology and glucose metabolism. Adv Neurobiol2016; 13: 275–294.
31.
SimonsMNaveKA.Oligodendrocytes: Myelination and axonal support. Cold Spring Harb Perspect Biol2015; 8(1): a020479.
32.
MoyonSMaDHuynhJL, et al. Efficient remyelination requires DNA Methylation. Eneuro2017; 4(2): ENEURO.0336-16.2017.
33.
LonsdaleD.Thiamine and magnesium deficiencies: Keys to disease. Med Hypotheses2015; 84(2): 129–134.
34.
KadayifciFZZhengSPanYX.Molecular mechanisms underlying the link between diet and DNA methylation. Int J Mol Sci2018; 19(12): 4055.
35.
MontaniLPereiraJANorrmenC, et al. De novo fatty acid synthesis by Schwann cells is essential for peripheral nervous system myelination. J Cell Biol2018; 217(4): 1353–1368.
36.
BadaraccoMESiriMVPasquiniJM.Oligodendrogenesis: The role of iron. Biofactors2010; 36(2): 98–102.
37.
TodorichBPasquiniJMGarciaCI, et al. Oligodendrocytes and myelination: The role of iron. Glia2009; 57(5): 467–478.
38.
SidikHTalbotWS.A zinc finger protein that regulates oligodendrocyte specification, migration and myelination in zebrafish. Development2015; 142: 4119–4128.
39.
SchraderMBendikIBecker-AndreM, et al. Interaction between retinoic acid and vitamin D signaling pathways. J Biol Chem1993; 268(24): 17830–17836.
40.
GuoYESuoNCuiX, et al. Vitamin C promotes oligodendrocytes generation and remyelination. Glia2018; 66(7): 1302–1316.
41.
CarrieIPortoukalianJVicarettiR, et al. Menaquinone-4 concentration is correlated with sphingolipid concentrations in rat brain. J Nutr2004; 134: 167–172.
42.
FerlandG.Vitamin K and the nervous system: An overview of its actions. Adv Nutr2012; 3(2): 204–212.
43.
DecollogneSTomasALecerfC, et al. NMDA receptor complex blockade by oral administration of magnesium: Comparison with MK-801. Pharmacol Biochem Behav1997; 58(1): 261–268.
44.
AllenGFNeergheenVOppenheimM, et al. Pyridoxal 5’-phosphate deficiency causes a loss of aromatic L-amino acid decarboxylase in patients and human neuroblastoma cells, implications for aromatic L-amino acid decarboxylase and vitamin B(6) deficiency states. J Neurochem2010; 114(1): 87–96.
45.
MachadoFRFerreiraAGda CunhaAA, et al. Homocysteine alters glutamate uptake and Na+,K+-ATPase activity and oxidative status in rats hippocampus: Protection by vitamin C. Metab Brain Dis2011; 26(1): 61–67.
46.
BallazSJRebecGV.Neurobiology of vitamin C: Expanding the focus from antioxidant to endogenous neuromodulator. Pharmacol Res2019; 146: 104321–104320.
47.
PadayattySJKatzAWangY, et al. Vitamin C as an antioxidant: Evaluation of its role in disease prevention. J Am Coll Nutr2003; 22(1): 18–35.
48.
WangXQuinnPJ.Vitamin E and its function in membranes. Prog Lipid Res1999; 38: 309–336.
49.
DringenRGuttererJMHirrlingerJ.Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur J Biochem2000; 267(16): 4912–4916.
50.
XavierAAPerez-GalvezA.Carotenoids as a source of antioxidants in the diet. Subcell Biochem2016; 79: 359–375.
51.
StahlWSiesH.Antioxidant activity of carotenoids. Mol Aspects Med2003; 24: 345–351.
52.
PiettaPG.Flavonoids as antioxidants. J Nat Prod2000; 63: 1035–1042.
53.
ReiterRJRosales-CorralSTanDX, et al. Melatonin as a mitochondria-targeted antioxidant: One of evolution’s best ideas. Cell Mol Life Sci2017; 74(21): 3863–3881.
54.
TibulloDLi VoltiGGiallongoC, et al. Biochemical and clinical relevance of alpha-lipoic acid: Antioxidant and anti-inflammatory activity, molecular pathways and therapeutic potential. Inflamm Res2017; 66(11): 947–959.
55.
ParmarSSJaiwalADhankherOP, et al. Coenzyme Q10 production in plants: Current status and future prospects. Crit Rev Biotechnol2015; 35(2): 152–164.
56.
BerridgeMJ.Vitamin D, reactive oxygen species and calcium signaling in ageing and disease. Phil Trans R Soc B2016; 371: 20150434.
57.
SepasiTHMoosavi-MovahediAA.Catalase and its mysteries. Prog Biophys Mol Biol2018; 140: 5–12.
58.
MiaoLSt ClairDK.Regulation of superoxide dismutase genes: Implications in disease. Free Radic Biol Med2009; 47(4): 344–356.
59.
LubosELoscalzoJHandyDE.Glutathione peroxidase-1 in health and disease: From molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal2011; 15(7): 1957–1997.
60.
LanganRCGoodbredAJ.Vitamin B12 deficiency: Tecognition and management. Am Fam Physician2017; 96(6): 384–389.
61.
WebbJL.Nutritional effects of oral contraceptive use: A review. J Reprod Med1980; 25(4): 150–156.
62.
YehudaSRabinovitzSMostofskyDI.Essential fatty acids and the brain: From infancy to aging. Neurobiol Aging2005; 26(Suppl. 1): 98–102.
63.
NeuIS.Essential fatty acids in the serum and cerebrospinal fluid of multiple sclerosis patients. Acta Neurol Scand1983; 67: 151–163.
64.
BjornevikKChitnisTAscherioA, et al. Polyunsaturated fatty acids and the risk of multiple sclerosis. Mult Scler2017; 23(14): 1830–1838.
65.
CalderPC.Omega-3 fatty acids and inflammatory processes: From molecules to man. Biochem Soc Trans2017; 45(5): 1105–1115.
66.
BadaraccoMEOrtizEHSotoEF, et al. Effect of transferrin on hypomyelination induced by iron deficiency. J Neurosci Res2008; 86(12): 2663–2673.
67.
MusallamKMTaherAT.Iron deficiency beyond erythropoiesis: Should we be concerned. Curr Med Res Opin2018; 34(1): 81–93.
68.
StankiewiczJMNeemaMCeccarelliA.Iron and multiple sclerosis. Neurobiol Aging2014; 35(Suppl. 2): S51–S58.
69.
SmoldersJDamoiseauxJMenheereP, et al. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol2008; 194(1–2): 7–17.
70.
SmoldersJDamoiseauxJ.Vitamin D as a T-cell modulator in multiple sclerosis. Vitam Horm2011; 86: 401–428.
71.
BhatMIsmailA.Vitamin D treatment protects against and reverses oxidative stress induced muscle proteolysis. J Steroid Biochem Mol Biol2015; 152: 171–179.
72.
EylesDAlmerasLBenechP, et al. Developmental vitamin D deficiency alters the expression of genes encoding mitochondrial, cytoskeletal and synaptic proteins in the adult rat brain. J Steroid Biochem Mol Biol2007; 103(3–5): 538–545.
73.
Pierrot-DeseillignyCSouberbielleJC.Vitamin D and multiple sclerosis: An update. Mult Scler Relat Disord2017; 14: 35–45.
74.
LucasRMByrneSNCorrealeJ, et al. Ultraviolet radiation, vitamin D and multiple sclerosis. Neurodegener Dis Manag2015; 5(5): 413–424.
75.
BaarnhielmMOlssonTAlfredssonL.Fatty fish intake is associated with decreased occurrence of multiple sclerosis. Mult Scler2014; 20(6): 726–732.
76.
HolickMF.The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord2017; 18(2): 153–165.
77.
MatuteCAlberdiEDomercqM, et al. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci2001; 24(4): 224–230.
78.
BenarrochEE.Oligodendrocytes: Susceptibility to injury and involvement in neurologic disease. Neurology2009; 72(20): 1779–1785.
79.
LeviteM.Glutamate, T cells and multiple sclerosis. J Neural Transm (Vienna)2017; 124(7): 775–798.
80.
AckroffKSclafaniA.Flavor preferences conditioned by dietary glutamate. Adv Nutr2016; 7(4): 845S–852S.
81.
HoltonKFTarenDLThomsonCA, et al. The effect of dietary glutamate on fibromyalgia and irritable bowel symptoms. Clin Exp Rheumatol2012; 30(6, Suppl. 74): 10–17.
82.
KaradottirRAttwellD.Neurotransmitter receptors in the life and death of oligodendrocytes. Neuroscience2007; 145(4):1426–1438.
83.
GonsetteRE.Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity. J Neurol Sci2008; 274(1–2): 48–53.
84.
PisoschiAMPopA.The role of antioxidants in the chemistry of oxidative stress: A review. Eur J Med Chem2015; 97: 55–74.
85.
HoltonK.The role of diet in the treatment of fibromyalgia. Pain Manag2016; 6(4): 317–320.
